| Domain | Metric | Value | Population/Study | Year | URL | Citation ID |
|---|---|---|---|---|---|---|
| Epidemiology | Annual incidence, Korea | 1.14–2.16 per 100,000/year | Nationwide Korean HIRA claims study; 8,678 incident HP cases | 2024 | https://doi.org/10.3346/jkms.2024.39.e96 | (pqac-00000024, pqac-00000026) |
| Epidemiology | Mean age / sex | 52.6 ± 18.9 years; 51.5% male | Nationwide Korean HIRA claims study | 2024 | https://doi.org/10.3346/jkms.2024.39.e96 | (pqac-00000026) |
| Epidemiology | ICD-10 coding | 82.2% coded J67.9 (HP due to unspecified organic dust) | Nationwide Korean HIRA claims study | 2024 | https://doi.org/10.3346/jkms.2024.39.e96 | (pqac-00000026) |
| Epidemiology | Bronchoscopy utilization | 16.9% | Nationwide Korean HIRA claims study | 2024 | https://doi.org/10.3346/jkms.2024.39.e96 | (pqac-00000024, pqac-00000025) |
| Epidemiology | No treatment within 1 year | 25.4% | Nationwide Korean HIRA claims study | 2024 | https://doi.org/10.3346/jkms.2024.39.e96 | (pqac-00000024) |
| Diagnostics | BAL lymphocytosis threshold vs IPF (fibrotic HP) | 20%: sensitivity 69%, specificity 61% | ATS/JRS/ALAT guideline evidence synthesis | 2020 | https://doi.org/10.1164/rccm.202005-2032ST | (pqac-00000017) |
| Diagnostics | BAL lymphocytosis threshold vs IPF (fibrotic HP) | 30%: sensitivity 55%, specificity 80% | ATS/JRS/ALAT guideline evidence synthesis | 2020 | https://doi.org/10.1164/rccm.202005-2032ST | (pqac-00000017) |
| Diagnostics | BAL lymphocytosis threshold vs IPF (fibrotic HP) | 40%: sensitivity 41%, specificity 93% | ATS/JRS/ALAT guideline evidence synthesis | 2020 | https://doi.org/10.1164/rccm.202005-2032ST | (pqac-00000017) |
| Diagnostics | Suggested practical BAL threshold | 30% considered reasonable by expert panel; no single definitive threshold validated | ATS/JRS/ALAT guideline summary | 2021 | https://doi.org/10.1513/AnnalsATS.202009-1195CME | (pqac-00000020) |
| Exposures | Identified inciting antigen | 66.8% | Prospective HP cohort (n=202) | 2023 | https://doi.org/10.1097/CM9.0000000000002613 | (pqac-00000006, pqac-00000030) |
| Exposures | Avian exposures among identified antigens | 50.4% | Prospective HP cohort (n=202) | 2023 | https://doi.org/10.1097/CM9.0000000000002613 | (pqac-00000006, pqac-00000030) |
| Diagnostics | Common HRCT findings | GGO 91.6%; reticulation 63.9%; traction bronchiectasis 48.5% | Prospective HP cohort (n=202) | 2023 | https://doi.org/10.1097/CM9.0000000000002613 | (pqac-00000006, pqac-00000030) |
| Biomarkers | BAL lymphocytosis present | 70.1% | Prospective HP cohort (n=202) | 2023 | https://doi.org/10.1097/CM9.0000000000002613 | (pqac-00000006, pqac-00000037) |
| Biomarkers | Predictor of fibrosis: BAL lymphocytes <20% | OR 2.47 | Prospective HP cohort (n=202) | 2023 | https://doi.org/10.1097/CM9.0000000000002613 | (pqac-00000006, pqac-00000037) |
| Biomarkers | Predictor of fibrosis: BAL eosinophils ≥1.75% | OR 2.36 | Prospective HP cohort (n=202) | 2023 | https://doi.org/10.1097/CM9.0000000000002613 | (pqac-00000006, pqac-00000037) |
| Biomarkers | Predictor of fibrosis: age ≥65 years | OR 2.61 | Prospective HP cohort (n=202) | 2023 | https://doi.org/10.1097/CM9.0000000000002613 | (pqac-00000006, pqac-00000037) |
| Prognosis | Radiologic fibrosis enrichment in fibrotic HP | Reticulation 96.5% vs 20.7%; honeycombing 40.0% vs 0%; traction bronchiectasis 82.6% vs 3.4% (FHP vs NFHP) | Prospective HP cohort (n=202) | 2023 | https://doi.org/10.1097/CM9.0000000000002613 | (pqac-00000037) |
| Prognosis | 1-, 3-, 5-year mortality | 3.9%, 16.8%, 32.7% | Biopsy-proven fibrotic HP cohort (n=101) | 2023 | https://doi.org/10.3389/fmed.2023.1131070 | (pqac-00000031, pqac-00000032) |
| Prognosis | Acute exacerbations | 19.8% | Biopsy-proven fibrotic HP cohort (n=101) | 2023 | https://doi.org/10.3389/fmed.2023.1131070 | (pqac-00000031) |
| Prognosis | Overall deaths during follow-up | 41.6% | Biopsy-proven fibrotic HP cohort (n=101) | 2023 | https://doi.org/10.3389/fmed.2023.1131070 | (pqac-00000031) |
| Prognosis | Fibrosis score performance for 5-year mortality | AUC 0.752; cutoff ≥12.0% | Biopsy-proven fibrotic HP cohort (n=101) | 2023 | https://doi.org/10.3389/fmed.2023.1131070 | (pqac-00000032) |
| Prognosis | Survival by fibrosis score | Mean survival 58.3 vs 146.7 months for fibrosis score ≥12.0% vs <12.0% | Biopsy-proven fibrotic HP cohort (n=101) | 2023 | https://doi.org/10.3389/fmed.2023.1131070 | (pqac-00000032) |
| Prognosis | Mortality/transplant predictor: age | HR 1.08 | Multicentre fibrotic HP cohort (n=403) | 2024 | https://doi.org/10.1183/23120541.00405-2023 | (pqac-00000033) |
| Prognosis | Mortality/transplant predictor: FVC % predicted | HR 0.96 | Multicentre fibrotic HP cohort (n=403) | 2024 | https://doi.org/10.1183/23120541.00405-2023 | (pqac-00000033) |
| Prognosis | Mortality/transplant predictor: BAL lymphocytosis | HR 0.93 | Multicentre fibrotic HP cohort (n=403) | 2024 | https://doi.org/10.1183/23120541.00405-2023 | (pqac-00000033) |
| Prognosis | Mortality/transplant predictor: acute exacerbation during follow-up | HR 3.04 | Multicentre fibrotic HP cohort (n=403) | 2024 | https://doi.org/10.1183/23120541.00405-2023 | (pqac-00000033) |
| Prognosis | Mortality/transplant predictor: GAP index | HR 1.96 | Multicentre fibrotic HP cohort (n=403) | 2024 | https://doi.org/10.1183/23120541.00405-2023 | (pqac-00000033) |
| Prognosis | Mortality/transplant predictor in biopsied subgroup: fibroblastic foci | HR 8.39 | Multicentre fibrotic HP cohort (biopsied subgroup) | 2024 | https://doi.org/10.1183/23120541.00405-2023 | (pqac-00000033) |
| Treatment | Annual FVC decline, placebo vs nintedanib | −187.8 vs −80.8 mL/year; difference 107 mL/year | INBUILD trial, progressive fibrosing ILD (26.1% HP) | 2023 review of trial data | https://doi.org/10.3390/ijms24097849 | (pqac-00000039) |
| Treatment | Risk reduction for relative FVC decline ≥10% predicted | 37% overall reduction | INBUILD whole-trial analysis | 2022 | https://doi.org/10.1183/13993003.04538-2020 | (pqac-00000043) |
| Treatment | Acute exacerbation of ILD or death | HR 0.67 (95% CI 0.46–0.98) | INBUILD whole-trial analysis | 2022 | https://doi.org/10.1183/13993003.04538-2020 | (pqac-00000043) |
| Treatment | Adverse event rate: diarrhea | 136.4 vs 23.0 events/100 patient-years (nintedanib vs placebo) | INBUILD whole-trial analysis | 2022 | https://doi.org/10.1183/13993003.04538-2020 | (pqac-00000043) |
| Treatment | Adverse event rate: nausea | 30.8 vs 7.6 events/100 patient-years | INBUILD whole-trial analysis | 2022 | https://doi.org/10.1183/13993003.04538-2020 | (pqac-00000043) |
| Treatment | Adverse event rate: vomiting | 17.3 vs 3.5 events/100 patient-years | INBUILD whole-trial analysis | 2022 | https://doi.org/10.1183/13993003.04538-2020 | (pqac-00000043) |
| Treatment | Adverse event rate: weight decrease | 12.4 vs 3.9 events/100 patient-years | INBUILD whole-trial analysis | 2022 | https://doi.org/10.1183/13993003.04538-2020 | (pqac-00000043) |
| Treatment | Adverse event rate: ALT increased | 12.4 vs 2.8 events/100 patient-years | INBUILD whole-trial analysis | 2022 | https://doi.org/10.1183/13993003.04538-2020 | (pqac-00000043) |
| Treatment | Real-world pre/post nintedanib FVC decline | −239.9 mL to −88.8 mL over 12 months; p=0.004 | UK multicentre real-world non-IPF PPF cohort (n=126) | 2023 | https://doi.org/10.1183/23120541.00423-2022 | (pqac-00000045) |
| Treatment | Real-world pre/post nintedanib DLCO decline | −6.1% to −2.1%; p=0.004 | UK multicentre real-world non-IPF PPF cohort (n=126) | 2023 | https://doi.org/10.1183/23120541.00423-2022 | (pqac-00000045) |
| Treatment | Real-world adverse events / persistence | 71% reported side effects; 80% of surviving patients remained on nintedanib at 12 months; no serious adverse events | UK multicentre real-world non-IPF PPF cohort (n=126) | 2023 | https://doi.org/10.1183/23120541.00423-2022 | (pqac-00000045) |
| Biomarkers | Plasma GDF15 to distinguish fibrotic vs non-fibrotic HP | 2539 ± 821 vs 1783 ± 801 pg/mL; cutoff 2193.4 pg/mL; AUC 0.75 | HP biomarker study (n=64 HP) | 2024 | https://doi.org/10.1038/s41598-023-49459-6 | (pqac-00000008) |


*Table: This table compiles key quantitative findings on hypersensitivity pneumonitis across epidemiology, diagnostics, prognosis, exposures, biomarkers, and treatment. It is designed as a compact evidence summary for rapid reference in a disease knowledge base or research report.*